1. Home
  2. ZURA vs TMS Comparison

ZURA vs TMS Comparison

Compare ZURA & TMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

N/A

Current Price

$4.09

Market Cap

455.4M

Sector

Health Care

ML Signal

N/A

Logo Teamshares Inc. Common Stock

TMS

Teamshares Inc. Common Stock

N/A

Current Price

$6.62

Market Cap

527.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ZURA
TMS
Founded
2022
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
527.4M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
ZURA
TMS
Price
$4.09
$6.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
4
Target Price
★ $18.00
$12.88
AVG Volume (30 Days)
★ 1.8M
100.9K
Earning Date
11-12-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$41.60
Revenue Next Year
N/A
$71.01
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.15
$5.04
52 Week High
$7.25
$10.10

Technical Indicators

Market Signals
Indicator
ZURA
TMS
Relative Strength Index (RSI) 36.17 41.03
Support Level $3.90 $5.31
Resistance Level $5.87 $9.58
Average True Range (ATR) 0.29 0.84
MACD 0.03 -0.17
Stochastic Oscillator 34.37 7.60

Price Performance

Historical Comparison
ZURA
TMS

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About TMS Teamshares Inc. Common Stock

Teamshares Inc is a tech-enabled company that acquires and operates small and medium-sized businesses. It uses a software platform to support activities across the acquisition lifecycle, including sourcing, evaluation, and transaction execution. After acquisition, the platform is used to integrate financial and operational data and to monitor performance across its portfolio companies. The company has two reportable segments: Small Business Acquisitions and Real Estate. The majority of revenue is derived from the Small Business Acquisitions, which includes all of the Operating Subsidiaries owned by the company.

Share on Social Networks: